Navigation Links
Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:8/4/2008

BETOL combination trial, the incidence of serious adverse events was 17% in the PEGINTRON/REBETOL groups compared to 14% in the INTRON A/ REBETOL group. The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23% in the INTRON A/REBETOL group and 31-34% in the PEGINTRON/REBETOL groups. Dose reductions due to adverse reactions occurred in 42% of patients receiving PEGINTRON (1.5 mcg/kg)/REBETOL and in 34% of those receiving INTRON A/REBETOL.

In a study with weight-based ribavirin, there was a higher rate of anemia among patients in the weight-based dosing group (29%) compared to the flat-dosing group (19%). The majority of these cases were mild and responded to dose reductions. Serious adverse events were similar between the two groups (12%), and discontinuations for adverse events (15% in weight-based dosing and 14% in flat dosing) were also similar. Dose modifications due to adverse events occurred more frequently in the weight-based dosing group (29%) compared to the flat-dosing (23%) group.

Additional Safety Information

Relapse of drug addiction/overdose has occurred in patients on PEGINTRON therapy. Aggressive behavior sometimes directed towards others has occurred in patients with and without a previous psychiatric disorder during PEGINTRON and/or INTRON A treatment and follow-up. If patients develop psychiatric problems, including clinical depression, it is recommended that patients be carefully monitored during treatment and in the 6-month follow-up period. If psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended that treatment with PEGINTRON and/or INTRON A be discontinued, and the patient be carefully followed with psychiatric intervention, as appropriate. Cases of encephalopathy have been observed in some patients, usually elderly, treated with higher doses of PEGINTRON and/or INTRON A. Ischemic and hemorrhagic cerebrovas
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
2. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
3. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
4. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
5. Inspires Phase 3 CF Trial, Using PARIs Nebulizer & Compressor, Shows Positive Top-Line Results
6. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
7. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
8. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
9. Schering-Plough Reports Top-Line Results of the IDEAL Study
10. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
11. Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... FRANCISCO , May 21, 2013 ... of the American Psychiatric Association show that the ... and clinically meaningful response and remission in patients ... phase of therapy, which were maintained through one ... treatment, 62 percent of patients achieved symptomatic improvement ...
(Date:5/21/2013)... 21 de mayo de 2013 La junta ... filiales incluyen OMNIlife science®, Inc., Enztec, Ltd. y Praxim, ... su junta. Guy Mayer, un ejecutivo ortopédico experimentado, será ... David Johnson , un experto refutado en ... Antes de unirse a OSI como presidente de ...
(Date:5/21/2013)... PRINCETON, N.J. , May 21, 2013 /PRNewswire/ ... consulting company, today announced that 13-year veteran ... Chief Executive Officer. Geraghty,s experience includes more than ... senior management positions with manufacturing organizations. He succeeds ... retiring after serving as Kepner-Tregoe,s Chairman of the ...
Breaking Medicine Technology:New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 3New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 4Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3
... Inc. (NYSE Amex: PTN ) announced that it ... Investment Conference / 12th Annual Healthcare Conference on Tuesday, September ... place September 12-15 at the New York Palace Hotel in ... and Chief Executive Officer of Palatin Technologies, will provide an ...
... HILL, N.C., Sept. 10 New Product Planning (NPP) ... new product development activities that set the stage for ... importance for NPP groups is medical marketing activities such ... Leading organizations understand that investing in educating the medical ...
Cached Medicine Technology:Best Practices, LLC Research Highlights Critical Role of Medical Marketing in New Product Launch Success 2
(Date:5/21/2013)... Beach, CA (PRWEB) May 21, 2013 ... 3rd Annual EB-5 Investment Summit: Dealmakers Conference in ... Dealmakers Conference will focus on exploring alternative finance ... provide the latest market, legal and economic information, ... immigration and legal professionals within the EB-5 industry. ...
(Date:5/21/2013)... Angeles, CA (PRWEB) May 21, 2013 According ... “Time to Rethink the Use of Botox,” Botox ... world since their approval in 2002 (Go to goo.gl/8iYbD). Although ... become quite popular with men. The injection makes facial wrinkles ... single Botox injection last for about three months. This means ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve ... the Creative Corridor region, is releasing results for its ... on Thursday, May 23rd at 10:30 a.m. The ... , The survey is a critical component to ... attract, nurture and retain people of diverse backgrounds, cultures ...
(Date:5/21/2013)... paper recently published in the New England Journal ... at the University of Colorado School of Medicine finds ... can be used to identify individuals at risk for ... fairly common variant of the gene for mucin-5B, a ... by the bronchial tubes. While this variant of the ...
(Date:5/21/2013)... Brazilian funding agency for scientific and technological research So ... So Paulo, announced an investment estimated in US$ 680 ... (RIDCs) for a period of up to eleven years, ... 7. , Funding for the 17 RIDCs will ... faculty, technicians, support personnel, and infrastructure). Host institutions will ...
Breaking Medicine News(10 mins):Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2
... SATURDAY, June 11 (HealthDay News) -- For most people, insect ... for those who are allergic to them, researchers warn. ... million people have to go to emergency departments after suffering ... American College of Allergy, Asthma and Immunology, which recently released ...
... HealthDay Reporter , FRIDAY, June 10 (HealthDay News) ... sex? That,s the finding from a new study ... of satisfaction in the bedroom. Researchers from Johns Hopkins ... than 3,200 men and women ages 18 to 26, analyzing ...
... News) -- Emotional abuse in childhood can lead to sleep ... analyzing nearly 900 adults ageD 60 and older, researchers found ... earlier were at greater risk for poor sleep quality years ... to exert an influence on our well-being decades later through ...
... 10 (HealthDay News) -- Men may be far less likely than ... they should make the effort, a Loyola University physician says. ... rates for heart disease, cancer, stroke and AIDS. But a U.S. ... to see a doctor on a regular basis. For many ...
... of medicine and director of the rheumatology division ... with colleagues from the medical center for rheumatoid ... and the blogosphere to discuss advances in the ... can be viewed at: , http://coe.musculoskeletaldisease.webdev.nyumc.org/research/whats-up-with-ra-webinar ...
... , THURSDAY, June 9 (HealthDay News) -- The U.S. Food ... a class of drugs used primarily to treat enlarged prostates, ... aggressive form of prostate cancer. In a statement released ... sold under the brand names Proscar and Propecia (sold by ...
Cached Medicine News:Health News:Insect Stings Hold Deadly Risk for Some 2Health News:Self-Confidence, Empathy May Make for Better Sex 2Health News:Self-Confidence, Empathy May Make for Better Sex 3Health News:Emotional Abuse in Childhood May Disrupt Sleep Decades Later 2Health News:Men Urged to Lead by Example and See a Doctor Regularly 2Health News:NYU Langone rheumatologists share insight with online RA community 2Health News:Drugs for Enlarged Prostate May Raise Risk of Aggressive Cancer 2Health News:Drugs for Enlarged Prostate May Raise Risk of Aggressive Cancer 3
... Eyes enzymatic cleaner is a ... removes stubborn deposits in as ... eyes enzymatic cleaner contains an ... irritating film on soft contact ...
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
Titanium. Straight shafts with curved lower tip. Upper tip fits into positioning hole while lower jaw stabilizes the lens. Flat smooth handle with dull finish. Most popular size or model....
Medicine Products: